American Society of Hematology

2017 ASH® Meeting on Hematologic Malignancies

September 08-09, 2017
Fairmont Chicago, Millennium Park, Chicago, IL

 Add to calendar 09/08/2017 07:00 AM09/09/2017 08:00 PMASH Meeting on Hematologic MalignanciesHear the top experts in hematologic malignancies discuss the latest developments in clinical care and find answers to your most challenging patient care questions.Fairmont Chicago, Millennium Park, Chicago, ILMM/DD/YYYY129600
      Get email updates

See what you missed at this year’s meeting!
Get full access to recordings of all “How I Treat” presentations and panel discussions from the 2016 ASH Meeting on Hematologic Malignancies.

Join us next year in Chicago for the 2017 ASH Meeting on Hematologic Malignancies and gain knowledge that can help you make an immediate impact on your practice. The meeting will feature the top experts in the field, comprehensive clinical content, the latest clinical research, and opportunities to interact with colleagues in an intimate, small-group setting with no competing sessions.

The program content will be structured as "How I Treat" presentations which will showcase each speaker's evidence-based treatment approaches, present cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and address what to do in cases where there is no data. Experts will provide out-of-the-box treatment approaches, answer challenging patient care questions during topic-based panel discussions, and engage in stimulating conversations on specific disease topics during Lunch with the Experts sessions.

The following core malignancies will be covered at the meeting:

  • Leukemia
  • Lymphoma
  • Myelodysplastic syndromes
  • Myeloma
  • Myeloproliferative neoplasms

Key Dates

Early-bird registration opens April 2017

Program Co-Chairs

Jonathan W. Friedberg, MD

Jonathan W. Friedberg, MD
University of Rochester

Ruben A. Mesa, MD

Ruben A. Mesa, MD
Mayo Clinic

Wendy Stock, MD

Wendy Stock, MD
University of Chicago

Program Planning Committee

  • Anjali Advani, MD, Cleveland Clinic
  • Jonathan W. Friedberg, MD, University of Rochester
  • John P. Leonard, MD, Weill Cornell Medical College
  • Ruben A. Mesa, MD, Mayo Clinic
  • Vincent Rajkumar, MD, Mayo Clinic
  • David Steensma, MD, Dana-Farber Cancer Institute
  • Wendy Stock, MD, University of Chicago

Confirmed Program Topics and Speakers

Leukemia

  • How I Treat ALL: Do All Adults with Ph+ ALL Still Require Allogeneic Transplant? – Wendy Stock, University of Chicago
  • How I Treat ALL: What are the Best Treatments for Relapsed ALL? – Anjali Advani, Cleveland Clinic
  • How I Treat CLL: Have the New Targeted Treatments Changed the "Watch and Wait" Approach? – Jennifer Woyach, Ohio State University
  • How I Treat AML: Which Patients Might Benefit from Hypomethylating Agents in the Frontline and at Relapse? - Gail Roboz, Weill Cornell Medical College
  • How I Treat AML: When the Patient Asks if AML can be Inherited, What Do I Tell Them? – Lucy Godley, University of Chicago

Lymphoma

  • How I Treat Follicular Lymphoma – Jonathan Friedberg, University of Rochester
  • How I Treat Mantle Cell Lymphoma – John Leonard, Weill Cornell Medical College
  • How I Treat Hodgkin Lymphoma – Nancy Bartlett, Washington University School of Medicine
  • How I Treat Non-Hodgkin Lymphomas: What Tests Do I Run to Diagnose and Follow Patients Across the NHL Spectrum? – Brad Kahl, Washington University in St. Louis
  • How I Treat T-Cell Lymphoma – Steven Horwitz, Memorial Sloan-Kettering Cancer Center

Myelodysplastic Syndromes

  • How I Use Molecular Diagnostic Tests in Patients with MDS or Suspected MDS – David Steensma, Dana-Farber Cancer Institute
  • How I Treat Patients with MDS Who Have Been Failed by Hypomethylating Agents – Amy Dezern, Johns Hopkins University
  • How I Choose Who To Transplant and Who Not To Transplant for MDS – Bart Scott, Fred Hutchinson Cancer Research Center

Myeloma

  • How I Treat Relapsed Myeloma – S. Vincent Rajkumar, Mayo Clinic
  • How I Treat Newly Diagnosed Myeloma – Noopur Raje, Massachusetts General Hospital
  • How I Treat MGUS and Smoldering Myeloma – Jesus San Miguel, University of Navarro

Myeloproliferative Neoplasms

  • How I Treat Patients with Progressive Myelofibrosis – Ruben Mesa, Mayo Clinic
  • How I Treat High-Risk Patients with Essential Thrombocythemia or Polycythemia Vera – Jason Gotlib, Stanford University
  • How I Treat CML: How to Monitor Patients, and When Should We Consider Discontinuation of Treatment? – Jerry Radich, Fred Hutchinson Cancer Research Center

Corporate Support

For information about sponsoring and/or exhibiting at this meeting, contact Thelma Barnett at tbarnett@hematology.org.

back to top